R&D News | pharmaphorum

News

Nippon Shinyaku’s DMD drug fails confirmatory trial

The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020

News

FDA sets date for Sarclisa in first-line multiple myeloma

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi

News

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

News

ADC developer Pheon raises $120m, and other bio financings

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine fi

Nippon Shinyaku’s DMD drug fails confirmatory trial

FDA sets date for Sarclisa in first-line multiple myeloma

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

ASCO: AffyImmune claims a first with CAR-T for solid tumours

ASCO: Merus bispecific garners attention after abstract drop

ADC developer Pheon raises $120m, and other bio financings

Lift for UK healthtech as fund bags £100m from national bank

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks